Rescheduling Headlines Move Cannabis Stocks, But the Policy Details Tell a Different Story
Tilray Brands surged in premarket trading after the U.S. Department of Justice announced it would reclassify FDA-approved and state-licensed medical cannabis products to Schedule III - then reversed